The first reported clinical results of a Phase I study following implantation of the 3-D neural interface retinal prosthesis showed it is safe in patients with end-stage retinitis pigmentosa.
EURETINA
Patrick Bussfeld, MD, VP, head medical affairs ophthalmology at Bayer Consumer Care AG, discusses the results from several treat-and-extend studies on aflibercept, and how Bayer is participating in the 2020 EURETINA virtual meeting.
Advertisement
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
One day, three approvals: FDA expands options for ocular redness, thyroid eye disease, and presbyopia
2
Brepocitinib meets all Phase 3 end points in noninfectious uveitis
3
Diabetic macular edema: an inflammatory disease in focus
4
Matching artificial tears to dry eye phenotype: a Q&A with Omur Ucakhan, MD
5